Please upgrade your browser.
It is particularly promising to see these high, durable responses in advanced NSCLC patients with low as well as high PD-L1 expression and in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies."
The drug, Fotivda, was approved for adults with advanced renal cell carcinoma -- the most common type of kidney cancer
Microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC) comprises Xp11 tRCC and t(6;11) RCC.
Michael B. Lawing from Rutherford County, NC is involved in advocacy for cancer patients at the local, National and International levels. He serves as a Member of the Board of Directors of the Kidney Cancer Association, the world’s largest non-profit dealing exclusively with Kidney Cancer with over 90,000 members in 102 countries.
The sNDA submission was based on positive results from phase II trial, CABOSUN, in patients with previously untreated advanced RCC with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
The research study, published online in the peer-reviewed journal Kidney Cancer, is important because it is the first report to demonstrate that the rising rate of kidney cancer seen in the U.S. over the past two decades may have ended.
...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.
While the guidance is only in its draft stage, the decision could mean that Eisai’s Kisplyx (lenvatinib) and Eusa Pharma’s Fotivda (tivozanib) are withheld from NHS patients in England and Wales.
This patent provides intellectual property protection for the ongoing human trial that evaluates the effect of the combination of GR-MD-02 with approved cancer immunotherapy drugs
In an interview with OncLive during ASCO, the study’s lead author, Toni Choueiri, MD, senior physician and director of the Kidney Cancer Center at Dana-Farber Cancer Institute, reflected on the avelumab/axitinib results and other emerging combos in RCC.
|NeonCRM by Neon One|